Literature DB >> 17091124

Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.

A Levin1, G L Bakris, M Molitch, M Smulders, J Tian, L A Williams, D L Andress.   

Abstract

Abnormalities of mineral metabolism occur early in chronic kidney disease. Quantification of the prevalence of these abnormalities has not been described using current assays nor in large unselected populations. This outpatient cohort cross-sectional study was conducted in 153 centers, (71% primary care practices). Blood for parathyroid hormone (PTH), vitamin D metabolites, creatinine, calcium (Ca), and phosphorus (P) were drawn between June and October 2004. Low 1,25-dihydroxyvitamin D (1,25 OH2 D3) was defined as <22 pg/ml. The 1814 patients had a mean age of 71.1 years old; 48% had diabetes mellitus (DM). Low 1,25 OH2 D3 was evident at all estimated glomerular filtration rate (eGFR) levels: 13% in those with eGFR >80 ml/min, >60% in those with eGFR <30 ml/min. High PTH (>65pm/dl) occurred in 12% with eGFR >80 ml/min. Serum Ca and P were normal until eGFR was <40 ml/min. Significant differences in the mean and median values of 1,25 OH2 D3, PTH, but not 25(OH)D3 levels, were seen across deciles of eGFR (P<0.001). Multivariate analysis revealed that DM, increased urinary albumin/creatinine ratio and lower eGFR predicted lower values of 1,25 OH2 D3. A high prevalence of mineral metabolite abnormalities occurs in a large unreferred US cohort. Low 1,25 OH2 D3 and elevated PTH are common at higher eGFR than previously described. As bone, cardiovascular disease, and mineral metabolite are correlated; further studies are necessary to determine the importance of these findings relative to outcomes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17091124     DOI: 10.1038/sj.ki.5002009

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  477 in total

1.  Development of Severe Hyperparathyroidism Despite Short-Term Renal Replacement Therapy.

Authors:  Manabu Okada; Yoshihiro Tominaga; Takahisa Hiramitsu; Toshihiro Ichimori
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

2.  Approach to cardiovascular disease prevention in patients with chronic kidney disease.

Authors:  Cristina Karohl; Paolo Raggi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

Review 3.  Can vitamin D slow down the progression of chronic kidney disease?

Authors:  Rukshana Shroff; Mandy Wan; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2011-12-10       Impact factor: 3.714

Review 4.  Vitamin D: roles in renal and cardiovascular protection.

Authors:  Yan C Li
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-01       Impact factor: 2.894

5.  Vitamin D, parathyroid hormone, and cardiovascular events among older adults.

Authors:  Bryan Kestenbaum; Ronit Katz; Ian de Boer; Andy Hoofnagle; Mark J Sarnak; Michael G Shlipak; Nancy S Jenny; David S Siscovick
Journal:  J Am Coll Cardiol       Date:  2011-09-27       Impact factor: 24.094

Review 6.  Nuclear receptors in renal disease.

Authors:  Moshe Levi
Journal:  Biochim Biophys Acta       Date:  2011-04-14

7.  Seasonal variation in 25-hydroxyvitamin D concentrations in the cardiovascular health study.

Authors:  Abigail B Shoben; Bryan Kestenbaum; Gregory Levin; Andrew N Hoofnagle; Bruce M Psaty; David S Siscovick; Ian H de Boer
Journal:  Am J Epidemiol       Date:  2011-11-23       Impact factor: 4.897

8.  Ethnic differences in 25-hydroxyvitamin D levels and response to treatment in CKD.

Authors:  Iris Sanchez; Roberto Mangoo-Karim; Jason R Stubbs; George P Yanev; James B Wetmore
Journal:  Int Urol Nephrol       Date:  2012-05-30       Impact factor: 2.370

Review 9.  Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.

Authors:  Kamyar Kalantar-Zadeh; Anuja Shah; Uyen Duong; Rulin C Hechter; Ramanath Dukkipati; Csaba P Kovesdy
Journal:  Kidney Int Suppl       Date:  2010-08       Impact factor: 10.545

Review 10.  The Causes of Hypo- and Hyperphosphatemia in Humans.

Authors:  Eugénie Koumakis; Catherine Cormier; Christian Roux; Karine Briot
Journal:  Calcif Tissue Int       Date:  2020-04-13       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.